This drug has shown in vitro and in vivo efficacy in combination with targeted therapies like EGFR inhibitors in EGFR mutation-positive NSCLC or BRAF/MEK inhibitors in BRAF mutation-positive melanomas [13–17]. This evidence concerns the gene BRAF and melanoma.